The Hypotonia Market is expected to reach USD 261.6 Million by 2030 at 8.2% CAGR during the forecast period 2022-2030.Hypotonia is also known as floppy baby syndrome, or weakness of muscles and lack of muscle tone. There are two main types of hypotonia – Acquired hypotonia in which hypotonia develops after birth as the result of an underlying medical condition, injury or trauma; and congenital hypotonia in which hypotonia is present at birth. Hypotonia is a symptom rather than a condition. Major causes of hypotonia can either be neurological or non-neurological.
Hypotonia is characterized with diminished muscle tone. The infant or child with hypotonic cerebral palsy appears floppy like a rag doll, hence the name. Hypotonic cerebral palsy is the result of an injury or malformation at an earlier brain developmental stage than that which causes spastic or choreoathetoid cerebral palsy. There are various causes of cerebral palsy which includes brain injury or brain malformation that occurs while the brain is developing i.e before, during, or after birth. As a result of the brain damage, during brain development, a child's muscle control, muscle coordination, muscle tone, reflex, posture and balance can be affected.
Neurological problems present at birth which affect a child's movement and co-ordination of brain and spinal cord injury including bleeding in the brain.
According to the World Health Organization estimates, neurological disorders are responsible for 4.5%-11% of all illnesses in the world including low or high income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.
However, limited availability of facilities and higher treatment cost may hamper the hypotonia market growth during the forecast period.
Figure: Global Hypotonia Market, By Region Market Share, 2016 (%)
Sources: Annual reports, Press release, White paper, Company presentation
The hypotonia market is segmented on the basis of types, diagnosis, treatment, and end user.
On the basis of the type, hypotonia market is segmented into acquired hypotonia and congenital hypotonia.
On the basis of diagnosis hypotonia market is segmented into physical examination, blood tests, muscle biopsy, assessment of cerebrospinal fluid, computerized tomography or CT scan or magnetic resonance imaging (MRI) scan, electroencephalogram, electromyography, metabolic panel tests, assessment of thyroid hormone, nerve conduction velocity, genetic testing, and others.
On the basis of treatment, hypotonia market is segmented into physiotherapy, occupational therapy, speech and language therapy, drugs, and others. Drugs is further segmented into neostigmine, physostigmine, and others.
On the basis of the end user, hypotonia market is segmented into hospitals & clinics, research laboratories and others.
The Americas dominate the hypotonia market owing to well-developed technology, increasing patient population, high health care spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the hypotonia market in this region.
Europe holds second position in the hypotonia market owing to government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, developed economies of the region such countries such as Germany and France are increasing investment in the healthcare domain and are focusing more on hospital infrastructure.
Asia Pacific is the fastest growing hypotonia market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing patient population in countries like India and South Korea are likely to emerge as the fastest growing hypotonia market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead the use of advanced equipment, which, in turn, may increase the market growth in this region.
On the other hand, the Middle East & Africa holds the least share of the hypotonia market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.
Some of key the players in the hypotonia market are LivaNova PLC (U.K), EnteroMedics Inc. (U.S.), ElectroCore Medical LLC (U.S.), Boston Scientific Corporation (U.S.), Cyberonics, Inc. (U.S.), NeuroMetrix, Inc.(U.S.), ImThera Medical (U.S.), and Inspire Medical Systems, Inc.(U.S.), and others.
Sources: Annual reports, Press release, White paper, and Company presentation
|Market Size||USD 261.6 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Types, Diagnosis, Treatment, and End User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||LivaNova PLC (U.K), EnteroMedics Inc. (U.S.), ElectroCore Medical LLC (U.S.), Boston Scientific Corporation (U.S.), Cyberonics, Inc. (U.S.), NeuroMetrix, Inc.(U.S.), ImThera Medical (U.S.), and Inspire Medical Systems, Inc.(U.S.), and others.|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||